Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

33.97
-0.7800-2.24%
Volume:2.46M
Turnover:83.01M
Market Cap:24.54B
PE:-72.28
High:34.56
Open:34.13
Low:33.32
Close:34.75
52wk High:42.50
52wk Low:15.90
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.85
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.80
PE(LYR):-62.91

Loading ...

How $950 Million Settlement Will Impact Roivant Sciences Stock (ROIV)

Simply Wall St.
·
Oct 07

Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million

Reuters
·
Oct 06

Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000

Reuters
·
Oct 03

Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer

Reuters
·
Oct 01

Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer

Reuters
·
Sep 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

TIPRANKS
·
Sep 24

Sector Update: Healthcare

MT Newswires Live
·
Sep 23

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Roivant Sciences price target raised to $41 from $37.50 at BofA

TIPRANKS
·
Sep 23

Immunovant Falls After Lupus Drug Setback

Reuters
·
Sep 23

Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE

Reuters
·
Sep 23

Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Sep 23

Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Roivant Sciences - All Other Clinical Development Timelines Remain on Track

THOMSON REUTERS
·
Sep 23

Roivant Sciences Holds Annual Shareholder Meeting

Reuters
·
Sep 18

Roivant Sciences Director Meghan FitzGerald Reports $203,159 Common Share Sale

Reuters
·
Sep 18

Stifel Nicolaus Initiates Roivant Sciences With Buy Rating, $51 Price Target

MT Newswires Live
·
Sep 17

Roivant Sciences Ltd : Stifel Initiates Coverage with Buy Rating; Target Price $51

THOMSON REUTERS
·
Sep 17

Roivant Sciences Price Target Announced at $51.00/Share by Stifel

Dow Jones
·
Sep 17